WallStSmart

Johnson & Johnson (JNJ)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 503494% more annual revenue ($99.33B vs $19.73M). JNJ leads profitability with a 16.2% profit margin vs 6.0%. ZJYL trades at a lower P/E of 20.8x. JNJ earns a higher WallStSmart Score of 54/100 (C-).

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 2.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64

ZJYL

Avoid

15

out of 100

Grade: F

Growth: 2.7Profit: 3.5Value: 5.3Quality: 5.5
Piotroski: 1/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JNJSignificantly Overvalued (-84.0%)

Margin of Safety

-84.0%

Fair Value

$145.14

Current Price

$270.47

$125.33 premium

UndervaluedFair: $145.14Overvalued

Intrinsic value data unavailable for ZJYL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

ZJYL1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

JNJ4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-95.9%2/10

Earnings declined 95.9%

ZJYL4 concerns · Avg: 3.0/10
Market CapQuality
$628.82M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.4%3/10

ROE of 3.4% — below average capital efficiency

Profit MarginProfitability
6.0%3/10

6.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bull Case : ZJYL

The strongest argument for ZJYL centers on Price/Book.

Bear Case : JNJ

The primary concerns for JNJ are Piotroski F-Score, PEG Ratio, P/E Ratio. A P/E of 43.0x leaves little room for execution misses.

Bear Case : ZJYL

The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.

Key Dynamics to Monitor

JNJ profiles as a mature stock while ZJYL is a value play — different risk/reward profiles.

ZJYL carries more volatility with a beta of 7.32 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (54/100 vs 15/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.

Want to dig deeper into these stocks?